ABSTRACTBACKGROUND: Bladder cancer (BC) is one of the ten most common types of cancer worldwide, with approximately 550,000 new cases each year. RESULTS: Urine samples from patients with G2 and G3 grade bladder cancer contained proteolytically active KLK13, as confirmed by kinetic analysis and immunochemical detection. DISCUSSION: Previous clinical study reveal the KLK13 significance for bladder cancer prognosis as increased KLK13 expression was highlighted in bladder tumors compared to normal adjacent tissues. KLK13 activity was confirmed in bladder cancer patients with G2 and G3 stage of disease development. CONCLUSION: Using specific chromogenic/fluorogenic peptides could be useful for the noninvasive disease monitoring of bladder cancer progress.

Source: New York Times October 29, 2021 08:20 UTC